Finally, we analyzed trends in the levels of DEF6 expression in cancer cell lines, which were lowest in kidney cancer, neuroblastoma, and liposarcoma cell lines and highest in leukemia, myeloma, and lymphoma cell lines (Figure 1D). This evidence concerns the gene DEF6 and plasma cell myeloma.